Aug 11, 2026, 13:05 UTC
DiaMedica Therapeutics reported its second-quarter progress and financial results, highlighting advancement of DM199 in early-onset fetal growth restriction, preeclampsia, and acute ischemic stroke, and a cash runway expected to extend through 2027.
Jun 23, 2026, 13:00 UTC
DiaMedica Therapeutics dosed the first patients in a Phase 2 trial of DM199 for treating fetal growth restriction.
Source: